Overview

Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer

Status:
NOT_YET_RECRUITING

Trial end date:
2033-12-31

Target enrollment:

Participant gender:

Summary

This study aims to evaluate the efficacy and safety of a PD-1 inhibitor combined with different chemotherapy regimens (PCb-EC and PCb), in order to develop a superior and well-tolerated neoadjuvant therapeutic strategy for patients with triple-negative breast cancer.

Phase:

PHASE2

Details

Lead Sponsor:

Henan Cancer Hospital

Treatments:

toripalimab